Generic medicine costs to rise?

Calls for Senate to reject bill forcing drug companies to disclose payments, fees and gifts to doctors

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The cost of generic medicines could rise, if a bill introduced by the Greens passes through government.

According to the Generic Medicines Industry Association (GMIA), the bill will place a significant administrative and cost burden on its members, which would need to be passed onto consumers through higher drug prices. As a result, GMIA has called on the Federal Senate to reject the bill.

The bill bans drug companies from paying to fly doctors to conferences and will force them to disclose payments, fees and gifts. Ken Harvey, Latrobe University associate professor says research has shown that too close a relationship between public health professionals and therapeutic companies was detrimental to public health.

“For example funding their travel and registration to attend conferences, payment for consultancy, company sponsored lectures, sitting on advisory boards all of this can encourage conscious or unconscious reciprocal by the recipients,” he said. “This can manifest itself in uncritical uptake of new, expensive and less well evaluated products and under-utilisation of more cost effective drugs and medical devices.”

Generic medicines are typically exact copies of brand name drugs, sold under a different name – such as “Chemist’s Own”. As they are generally lower in price than the brand name products, margins for the generic drug makers will typically be lower than their usually larger brand name competitors.

Sigma Pharmaceuticals (ASX: SIP), together with Australian Pharmaceutical Industries (ASX: API) and the unlisted Symbion controlled the majority of Australia’s drug wholesaling market, until Sigma sold its pharmaceuticals business in 2011 to Aspen Pharmacare.

Foolish takeaway

No matter whether the bill gets passed by the Senate or not, both Sigma and API are well positioned to take advantage of Australia’s aging population, along with Ramsay Health Care Limited (ASX: RHC) and Primary Healthcare Limited (ASX: PRY).

The dramatic run-up in the ASX 50 means many of our Aussie “blue chips” are trading for truly eye-popping prices. That’s why savvy investors are now seeking opportunity in smaller companies. Discover two fantastic small-cap opportunities now, in The Motley Fool’s brand-new research report, Two Small Cap Superstars — including names, codes, and all the details. Simply click here to download your FREE copy.

More reading

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.  This article contains general investment advice only (under AFSL 400691). Motley Fool writer/analyst Mike King doesn’t own shares in any companies mentioned.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

person reading news on mobile phone
⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »